Table 4.

Non-hematologic adverse events observed in either cohort (AML and MDS/CMML), regardless of causality

Parameter	Grade 1–2	Grade 3	Grade 4	Grade 5
Acute coronary syndrome	0	0	1 (2%)	0
Acute kidney injury	0	1 (2%)	1 (2%)	0
Anorexia	2 (5%)	1 (2%)	0	0
Atrial fibrillation	0	1 (2%)	0	0
Cholecystitis	0	2 (5%)	0	0
Dehydration	0	1 (2%)	0	0
Delirium	0	1 (2%)	0	0
Disease progression	0	0	0	1 (2%)
Enterocolitis	0	3 (8%)	0	0
Fatigue	4 (10%)	0	0	0
Febrile neutropenia	0	9 (23%)	1 (2%)	0
Fluid overload	0	1 (2%)	0	0
Generalized muscle weakness	0	1 (2%)	0	0
Gastrointestinal hemorrhage	0	0	0	1 (2%)
Hyperglycemia	0	3 (8%)	0	0
Hypokalemia	0	2 (5%)	0	0
Hypophosphatemia	6 (15%)	9 (23%)	0	0
Hyponatremia	0	1 (2%)	0	0
Hypotension	1 (2%)	1 (2%)	0	0
Increased ALT/AST	4 (10%)	3 (8%)	1 (2%)	0
Increased bilirubin	2 (5%)	3 (8%)	0	0
Infection	0	16 (35%)	0	1 (2%)
Insomnia	0	1 (2%)	0	0
Intracranial hemorrhage	0	0	1 (2%)	0
Multi-organ failure	0	0	0	1 (2%)
Nausea/vomiting	4 (10%)	2 (6%)	0	0
Oral mucositis	1 (2%)	1 (2%)	0	0
Pain (extremities/back)	0	3 (8%)	0	0
Pneumonitis	0	2 (5%)	0	0
Rash (acneiform)	0	1 (2%)	0	0
Sepsis	0	0	2 (5%)	0
Small bowel obstruction	0	2 (5%)	0	0
Stroke	0	0	0	1 (2%)
Sudden death	0	0	0	2 (5%)
Syncope	0	1 (2%)	0	0

ALT, alanine aminotransferase; AST, aspartate aminotransferase

Data are n (%). Any grade 1–2 adverse event occurring in ≥ 10% of patients, and all grade 3, 4 and 5 adverse events are included